Myriad Genetics (MYGN) Cash & Equivalents (2009 - 2026)

Myriad Genetics (MYGN) has reported Cash & Equivalents for 18 consecutive years, with $124.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 35.51% year-over-year to $124.4 million; the TTM figure through Mar 2026 stood at $124.4 million (up 35.51% YoY), while the FY2025 annual figure was $149.6 million, up 46.09% from the prior year.
• Cash & Equivalents eased to $124.4 million in Q1 2026 per MYGN's latest filing, from $149.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $164.2 million in Q1 2022 and bottomed at $53.6 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $104.5 million across 5 years, with a median of $102.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 77.89% — and 2023, when it surged 132.16%.
• Myriad Genetics' Cash & Equivalents stood at $56.9 million in 2022, then jumped by 132.16% to $132.1 million in 2023, then retreated by 22.48% to $102.4 million in 2024, then jumped by 46.09% to $149.6 million in 2025, then slipped by 16.84% to $124.4 million in 2026.
• Business Quant data shows MYGN's Cash & Equivalents at $124.4 million in Q1 2026, $149.6 million in Q4 2025, and $145.4 million in Q3 2025.